Little is known about metastatic pathways that are specific to the lung rather than other organs. We previously showed that antioxidant proteins such as peroxiredoxins were specifically upregulated in lung metastatic breast cancer cells. We hypothesize that cancer cells that live under aerobic conditions, as might be the case in lungs, protect themselves against the damage caused by reactive oxygen species (ROS). To examine this hypothesis, we studied the role of peroxiredoxin-2 (PRDX2) in lung vs bone metastasis formation. A metastatic variant of MDA-MB-435 breast cancer cells that specifically metastasize to lungs (435-L3) was transduced with short hairpin RNAs to specifically silence PRDX2. Conversely, a bone metastatic variant of MDA-MB-231 cells (BO2) was stably transfected to overexpress PRDX2. The 435-L3 cells silenced for PRDX2 were significantly more sensitive to H 2 O 2 -induced oxidative stress than the parental and scrambled transfected cells. BO2/PRDX2 cells produced less ROS than BO2/green fluorescent protein control cells under oxidative stress. Moreover, PRDX2 knockdown inhibited the growth of 435-L3 cells in the lungs, whereas lymph node metastasis remained unaffected. In contrast, PRDX2 overexpression in bone metastatic BO2 breast cancer cells led to drastic inhibition of the skeletal tumor burden and reduction of bone destruction. Furthermore, PRDX2 expression in breast cancer cells was associated with a glucose-dependent phenotype, different from bone metastatic cells. Overall, our results strongly suggest that PRDX2 is a targetable 'metabolic adaptor' driver protein implicated in the selective growth of metastatic cells in the lungs by protecting them against oxidative stress.
INTRODUCTION
The development of metastatic capacity is due to the acquisition of specific characteristics that accompany tumor cells during malignant progression in the local environment and at distant sites. 1 As migratory tumor cells are confronted by different microenvironments, which they must survive and eventually counteract, 'cross-talk' between metastatic cells and these microenvironments is needed for metastasis development. 2 Indeed, the interactions between early disseminated cancer cells and the surrounding tissues lead to the selection or adaptation of the cells in an early metastatic niche previous to metastasis outgrowth. 3 Additional genetic or epigenetic events and/or release from dormancy are critical for the productive metastatic growth of early disseminated cancer cells. 4 Moreover, primary breast tumors might contain 'cancer stem cells' that can metastasize and drive the formation and growth of new tumors. 5 After bone, lung is the second main target of breast cancer metastasis. Transcriptomic analysis of a variety of cell lines has identified the genes that mediate metastasis to bone or lungs. 6 --8 Different tropisms to bone and lungs have recently been associated with discrete variations in overall gene expression patterns. Thus, specialized gene sets have been defined that mediate metastasis to these target organs. 4, 7, 9 Moreover, many key oncogenic signaling pathways converge to adapt tumor cell metabolism to support their growth and survival. 10 By proteomic comparison of metastatic breast cancer cell lines, we found several antioxidant proteins, such as peroxiredoxins, that were specifically upregulated in lung metastatic cells compared with other organ-specific metastatic variants. 11 Indeed, cells living under aerobic conditions, as might be the case in lung metastasis, protect themselves from the damage caused by reactive oxygen species (ROS), which arises from the incomplete reduction of oxygen or exposure to external agents. 12 --16 During a recent protein --protein interaction network analysis of breast cancer cells that metastasize in lungs, we found that peroxiredoxin-2 (PRDX2) interacted with 105 different proteins. 17 Thus, we hypothesized that PRDX2 is a key phenotype with an important role in antagonizing oxidative stress in breast cancer cells that metastasize in lungs.
Here, we show that PRDX2 expression in breast cancer cells buffers metastatic cells against oxidants, as a virulent phenotype specifically selected by the lung microenvironment. This suggests a putative role of PRDX2 in stratifying patients at first diagnosis for a more specific therapy that might be based on ROS-inducing drugs.
RESULTS
Expression patterns and subcellular distribution of peroxiredoxins in lung metastatic MDA-MB-435 breast cancer cells We first examined human peroxiredoxin expression (PRDXs 1 --6) in parental 435-P cells and their metastatic variants to validate their differential expression, according to previously reported data. 11 We found that PRDX2 and PRDX3 levels were higher in lung metastatic variants (435-L 2 , 435-L 3 and 435-L 2/5 ) than in 435-P cells and lymph node (435-N) or bone (435-B) metastatic variants (Figure 1a , left panel). The more aggressive 435-L 3 cell line showed the highest overall level of peroxiredoxin expression (12 times more) compared with parental cells ( Supplementary Table S1 ).
Furthermore, we used confocal laser scanning microscopy to investigate the compartmental subcellular distribution of PRDX2 and PRDX3. PRDX3 was localized in the mitochondria, whereas PRDX2 was cytosolic (Figure 1a , right panel). Moreover, PRDX2 translocated from the cytosol to the nucleus in response to an oxidant challenge with its substrate hydrogen peroxide (3 mM), while PRDX3 remained localized in the mitochondrial membrane (Figure 1a , right panel). PRDX2 protein translocation under oxidative stress was similar in 435-P and 435-L 3 metastatic cells. Hence, PRDX2 and PRDX3 may exert their antioxidant activity in different cellular compartments without redundancy to control intracellular ROS.
Lung metastatic MDA-MB-435 breast cancer cells have increased oxidative stress resistance We analyzed the oxidative stress response in 435-P and lung metastatic variants 435-L 2 and 435-L 3 to investigate the relationship between PRDX expression and the cell's ability to resist oxidative stress. The cells showed dose-dependent resistance to oxidative stress ( Figure 1b ). We found that parental cells were more susceptible to oxidative stress than their lung metastatic variants ( Figure 1b ). This was evident at a concentration of 2 mM H 2 O 2 and even more marked at a concentration of 3 mM H 2 O 2 , at which the viability of 435-L 3 cells was twice as high as parental cells (60% vs 30%, Po0.01). At this concentration, the viability of the less aggressive 435-L 2 cells was also still higher than that of the parental cells (40% vs 30%, Po0.01). This correlated well with the overall levels of peroxiredoxins detected in these cells. We further determined the internal generation of ROS in 435 cells, using 2 0 ,7 0 -dichlorofluorescein diacetate (DCFH 2 -DA) as a ROS scavenger ( Figure 1c ). 435-L 3 cells produced lower amounts of ROS than 435-P cells in physiological conditions, and this effect was maintained under oxidative stress (Po0.05 for both conditions). The ratios of ROS production in basal vs oxidative stress conditions were similar in both cell lines (435-P, 0.46; 435-L 3 , 0.37), which indicates a similar increase in cellular stress levels. Furthermore, we examined the oxidative state of PRDXs in basal conditions and under oxidative stress by measuring PRDX-SO 3 , which is the irreversibly overoxidized form of PRDX. Figure 1d shows that under severe oxidative stress, inactive PRDX-SO 3 accumulated more in parental than in lung metastatic cells. This suggests that there was a higher degree of depletion of active PRDX in 435-P cells via inactivation of the peroxidase function and subsequent PRDX degradation. 18 The used of a histone deacetylase inhibitor valproic acid, which causes an accumulation of ROS in transformed cells, 19 confirmed that the ROS-generating agents counteracted PRDXs and prevented breast cancer lung metastasis (Supplementary Figure S1 ). Downregulation of PRDX2 sensitizes lung metastatic MDA-MB-435 breast cancer cells against ROS To investigate whether peroxiredoxins provide lung metastatic cells with more effective protection against oxidative stress, we transiently depleted 435-L 3 cells of PRDX2 or PRDX3 using small interfering RNA oligos (Supplementary Figure S2A ). Knockdown of PRDX2 or PRDX3 sensitized cells against H 2 O 2 and induced more stress than in nontransfected 435-L 3 cells (Supplementary Figure S2B ). Moreover, intracellular ROS levels increased in 435-L 3 cells that were transiently depleted of PRDX2 and PRDX3 when cells were exposed to H 2 O 2 (Supplementary Figure S2C ). Interestingly, cells depleted of PRDX2 had significantly higher basal levels of ROS than untransfected 435-L 3 cells, 435-L 3 cells transfected with a control oligo, and siPRDX3-transfected cells (Supplementary Figure S2C ). This indicates that the ROS scavenger function of PRDX2 in lung metastatic cells was greater than that of PRDX3.
We therefore decided to stably downregulate PRDX2 expression in 435-L 3 -eGFP-CMV/Luc cells to further investigate the consequences of elevated PRDX2 in lung metastatic breast cancer cells in vivo. PRDX2 expression was verified by western blot analysis and quantitative PCR (Figure 2a and Supplementary Figure S3A ). Plots of the amount of light produced by predetermined numbers of 435-L 3 /scbl cells vs the number of cells were linear throughout the range of cells tested (R 2 ¼ 0.9928). This shows that light measurements can be used to estimate cell numbers (Supplementary Figure S3B ). We chose a stably downregulated clone (shPRDX2, clone #7) with low protein expression, as well as a pool of control clones transfected with the scrambled version of PRDX2 (scbl) for further characterization (Figure 2a ). shPRDX2 cells showed significantly higher sensitivity to H 2 O 2induced oxidative stress ( Figure 2b ) than 435-L 3 and scbl control cells (Po0.0005 for both cell lines). Production of internal ROS correlated well with PRDX2 levels in cells under basal and oxidative stress conditions ( Figure 2c ). 435-P cells had the highest ROS in basal conditions, which increased in the presence of H 2 O 2 . Moreover, basal ROS that was not modified in shPRDX2 cells, showed significantly increase in stress conditions. No significant differences in cell cycle characteristics were found under basal or oxidative stress conditions, as revealed by flow cytometry (Figure 2d ).
PRDX2 has a cause --effect role in lung metastasis
To examine whether downregulation of PRDX2 in lung metastatic cells affects their metastatic capacity and their propensity to grow in the lungs, we induced intra-mammary fat pad orthotopic tumors by inoculating nude mice (n ¼ 7 per group) with a PRDX2 knockdown clone (shPRDX2, clone #7) or with control cells (scbl). Tumorigenesis and metastatic progression in animals was monitored periodically (Figures 3a and b ). Statistical analysis using a linear model algorithm to compare PRDX2 knockdown cells and the scbl control cells showed that, 40 days after cell inoculation, the tumors in mice inoculated with shPRDX2 cells tended to be smaller (82.8 ± 47.0 mm 3 ) than the scbl control tumors (187.9±97.5 m 3 ). However, these differences in tumor volume were not significant (P ¼ 0.165). Moreover, the metastatic progression to lungs after tumor induction, as quantified from the normalized photon flux of cancer cells, differed between groups (Supplementary Figure S4A ). By the end of the protocol at day 82, the normalized photon flux differences were significant between scbl and shPRDX2 groups (Po0.005). Indeed, although all of the mice developed primary tumors in both groups, the metastasis incidence in mice bearing shPRDX2 tumors was substantially different from that observed in control animals (incidence: 14% vs 86%, respectively) ( Figure 3b ). To avoid bias in metastatic evolution because of differences in primary tumor size, we evaluated the global incidence of lung metastasis in each group relative to the primary tumor size at the time of tumor exeresis by PRDX2 promotes lung metastasis V Stresing et al calculating the normalized photon flux ratios of metastasis/tumor for each animal (Supplementary Figure S4B ). The differences in metastatic capacity were significant at the end of the experiment (Po0.005).
We further examined the ex vivo expression of PRDX2 in tumor samples from shPRDX2 tumor-bearing mice and control animals by immunohistochemistry analysis. As expected, stable knockdown of PRDX2 persisted in breast tumors and in metastatic tissues ( Figure 3c ). Furthermore, there were no differences among tumors in proliferating cell nuclear antigen staining as a marker of proliferation; expression was high in all breast tumors at the time of exeresis (Figure 3c ). In contrast, increased cell death as indicated by caspase-3 activation was evident in shPRDX2 tumors relative to controls. Hence, there may be a negative imbalance between cell proliferation and cell death in shPRDX2 net tumor growth as a consequence of PRDX2 downregulation (Figure 3c ), which favored cell death.
Moreover, we examined the expression of endothelial marker CD31 as an indicator of neovasculature in breast tumors ( Figure 3d ). Although similar numbers of vessels were produced in all groups, a parametric Wilcoxon test revealed that tumors from shPRDX2 mice had a significantly lower value for vascular lumen than control tumors (Po0.05). With regard to blood vessel structure in lung metastases, no vasculature was formed in the single case of shPRDX2 lung metastases, unlike metastases from control mice ( Table 1) .
We analyzed PRDXs gene expression profiling across a series of breast tumors, GSE2603. 6 Although we did not find significant PRDX2 promotes lung metastasis V Stresing et al association between PRDX2 gene expression and lung metastasis free survival, the total of PRDXs was significantly associated with lung metastatic progression (P ¼ 0.0055) but not with the rest of metastases (P ¼ 0.077), suggesting that PRDX2 function might be regulated at the protein level ( Supplementary Table S2 ). Moreover, PRXD2 expression in a breast cancer tissue array from 104 patients showed that high expression of PRDX2 in breast carcinomas trend to lung metastasis progression, Po0.053 (Supplementary Figure S5 ). 
Downregulation of PRDX2 specifically inhibits the growth of metastatic cells in lungs
We then intravenously injected shPRDX2 and scbl control cells and monitored the homing of cells to the lungs over time. There was a time-dependent increase in the shPRDX2 and scbl cell burden in lungs. The number of scbl cells retained there was statistically significantly higher until the end of the experiment at day 55 (P ¼ 0.056) than that observed in lungs of mice injected with shPRDX2 cells (Figure 4a ). Whole-body in vivo imaging of animals confirmed that the lung metastasis burden was substantially lower in mice inoculated with shPRDX2 cells than in control mice, whereas the burden of scbl and shPRDX2 cells in lymph nodes was similar ( Figure 4b ). Furthermore, hematoxylin and eosin staining and optical microscopy showed higher lung colonization in control mice (Figure 4c ) than in shPRDX2 mice. An analysis of green fluorescent protein (GFP)-positive cells in ex vivo lung PRDX2 promotes lung metastasis V Stresing et al samples of mice injected with shPRDX2 and scbl cells confirmed the in vivo results. We examined the lymph node PRDX2 expression by immunohistochemistry and found that it was low and similar in all samples (Figure 4c ). The evolution of lung metastasis in controls limited the course of the experiments. Thus, by the time lung and lymph node metastasis had developed no signal compatible with bone metastasis was detected.
If during metastasis formation cells that reach lungs are selected by their ability to remove ROS and PRXD2 is an exponent of this organe-specific phenotype, we wondered why PRXD2 also decreased in metastasis from hypoxic tissue like bone (Figure 1a and Supplementary Table S1 ). We stably overexpressed PRDX2 in the highly bone metastatic BO2-GFP/tTA cell line (selected from six in vivo/in vitro passes), which expressed low levels of the protein (Figure 5a , left panel). Two clones (#10 and #88) overexpressing PRDX2 were obtained (Supplementary Figure  S6A) . Clone #88 was selected for further studies as the luciferase expression levels were similar to those expressed by the BO2/GFP control cell line, thereby allowing direct comparison by bioluminescence imaging in bone metastasis experiments in vivo (Supplementary Figure S6B ).
Overexpression of PRDX2 in BO2 cells (Figure 5a , left panel) was inversely correlated with intracellular ROS production (Figure 5a , right panel); BO2/PRDX2 cells produced less ROS than BO2/GFP control cells in basal conditions (Po0.05) and under oxidative stress stimuli (Po0.005).
We next examined the effect of overexpression of PRDX2 on breast cancer bone metastasis formation. BO2/PRDX2 cells (clone #88) and BO2/GFP control cells were inoculated intracardiacally into nude mice (n ¼ 6 per group). A radiographic analysis of hind legs at day 36 and day 40 after tumor cell inoculation showed that mice bearing BO2/PRDX2 tumors had significantly smaller osteolytic lesions than mice injected with BO2/GFP cells (Figure 5b, left panel) . The mean area of osteolytic lesions at day 40 was 5.1 ± 2.9 mm 2 and 15.8 ± 1.6 mm 2 for BO2/PRDX2 and BO2/ GFP tumor-bearing animals, respectively (Po0.005). Bioluminescence imaging of mice revealed that the BO2/PRDX2 tumor burden in animals was statistically significantly less than that observed in control mice injected with BO2/GFP cells (Po0.05). This indicates that PRDX2 overexpression impaired BO2 cell growth in bones (Figure 5c ).
The decreased in vivo skeletal growth of BO2/PRDX2 cells, in contrast to the effect of PRDX2 in lung metastatic cells, suggested that PRDX2, which protected lung metastatic cells against oxidative stress, did not improve bone metastatic cell colonization.
Next, we performed experiments to visualize in vivo the metabolic features of metastatic bone lesions using radiopharmaceuticals that target tumors cells with a high glycolytic metabolism ([ 18 F]FDG) or bind to bone ([ 18 F]NaF). The positron emission tomography (PET) scan of animals did not show any accumulation of FDG in metastatic hind limbs (Figure 5d , middle panel), despite the presence of BLI-positive tumor cells (Figure 5d, left panel) . In contrast, there was a far greater accumulation of NAF in hind limbs (Figure 5d, right-hand panel) , which confirms the presence of osteolytic lesions.
PRDX2 regulates the metabolic stress response of lung metastatic cells We used Raman microspectroscopy to study the chemical composition of metastatic variants to assess the importance of the metabolic pressure of the target organ to select the metabolic phenotype of metastatic cells (Supplementary Figure S7) .
The principal component analysis models using the spectral region 600--1700 cm À1 differentiated the data set of lung metastatic 435-L3 cells from the bone metastatic 435-B cells, (Supplementary Figures  S7A and B ). Loadings on PC3 containing the bands: 1003 cm À1 , trigonal ring breathing of the benzene ring (present in phenylalanine residue); 1443 cm À1 , methylene scissoring deformation and 1655 cm À1 , HC¼ CH stretch (cis conformation), compatible with fatty acids and protein; and loadings on PC4, bands in region 729 and 1617 cm À1 , compatible with NADH, were involved (Supplementary Figure S7B ). Under glucose deprivation, 435-L3 and 435-B metastatic cells were almost completely separated by the PC4 component, which increased in bone metastatic cells. Moreover, chemical hypoxia shifted each variant in opposite PC3 way: while 435-B increased PC3 value, the 435-L3 cells decreased it (Supplementary Figure S7C ). These results indicated that metastatic variants had different metabolic phenotype and can be separated by their different metabolic features.
To further explore the role of PRDX2 in the selection of cells according the bioavailability of glucose in the target organ, we challenged cells from both breast cancer models, 435-P (lung metastatic tropism) and 231 cells (bone metastatic tropism) and their metastatic variants through starving them from glucose (Figure 6a ). 435-L3 cells survived significantly more than 435-P cells (Po0.0005). As 435-P and 435-L3-shPRDX2 had only 50% of viability, the data suggested that PRDX2 provided 435-L 3 cells with the ability to the preferential use of glucose. In addition, PRDX2induced BO2 cells more susceptible against glucose deprivation with regard to parental cells (P ¼ 0.016), suggesting that PRDX2 disturbed the metabolic switch of the bone glucose-independent cells. Moreover, 435-B cells (P ¼ 0.001) and BO2 cells (P ¼ 0.003) were less affected by hypoglycemic conditions, with regard their respective control cells. The putative glucose dependence metabolism of lung metastatic cells was checked by measuring the lactate production of 435-L3 and 435-B cells with regard to protein concentration: 435-L3 had 20.88 mM and 435-B had 14.57 mM lactate/mg protein. These results suggested the glycolytic phenotype of lung metastatic cells and indicate that the overexpression of PRDX2 in lung metastatic cells might subtend the preferential use of glucose (Figure 6b ).
DISCUSSION
The lung receives many cancer cells transported in the blood stream, however, the majority of pro-metastatic cells are destroyed in lungs, which act as a filter that involves the activation of alveolar macrophages. 20 Thus, the levels of partial oxygen pressure that metastatic cells can suffer in lungs are different from those experienced in other systemic tissues. 21, 22 We have demonstrated that PRDX2 overexpression in lung metastatic cells effectively removes the intracellular ROS, suggesting that this phenotype is helpful in the lung microenvironment to metastatic cell colonization. The scavenger ability of cells overexpressing PRXD2 might counteract the ROS delivered by the preferential use of glucose, primed in the lung microenvironment, allowing metastases grow by shortening the dormancy period. PRDX2 is a highly efficient redox protein that neutralizes hydrogen peroxide, resulting in protection of cells from oxidative damage and in regulation of peroxide-mediated signal transduction events. 23 Its unique redox properties may account for nonredundant role in defense against oxidative stress. Indeed, metastatic cells that overexpress PRDX2 might mimic normal erythrocytes and lung cells that are well-buffered against exogenous oxidants and oxidative stress metabolism. 24 PRDX2's pathogenic function is driven by a mechanism of protein regulation against its irreversible hyperoxidation. 25 Indeed, lung metastatic cells had the highest PRXD2 level and the lowest hyperoxidation. Preventive therapies with ROS-inductor drugs diminished lung metastasis. Therefore, several ROS-generating agents like histone deacetylase inhibitors 19 and the glycopeptide antibiotic Bleomycin, 26 might perform preventive therapeutic strategies overtaking PRXD2 function. Conoiding A is a novel inhibitor of this important class of antioxidant and redox signaling enzymes 27 that binds covalently to the peroxidatic cysteine of TgPrxII blocking its enzymatic activity. On the other hand, drugs such as 6-amino-nicotinamide, which inhibits G6P dehydrogenase 28 might be effective against bone metastatic cells that had increased the NADH levels. Additional basic and in vivo experiments are needed to answer these questions.
The mechanism of the high use of glucose under aerobic conditions is still debated. The highly glycolytic phenotype of cancer cells was reported to be induced by activation of the oncogene Akt. 29 The clear differences in the metabolic phenotype of lung and bone metastatic cells raise questions about preventive therapies according the mimetic metabolic features that metastatic cells can acquire in the target organ. Indeed, the mechanism to cope with the cumulative ROS is different in lung than in bone tissues, where the lowest oxygen gradient in bone marrow induces fewer metabolic free radical challenges. 30 Moreover, PRDX2 is produced by bone marrow stromal cells and regulate the hydrogen peroxide level of this complex niche. 31 PRDX2 influences oxidative and metabolic stress through multiple mechanisms. 23 As PRDX2 knockdown dramatically decreases lung metastasis formation, we suggest that PRDX2 is a 'metabolic adaptor', which functions stabilizing the redox state required for cell survival in an oxidative atmosphere. Indeed, and effective anti-oxidant defense system is needed to protect metastatic cells from free radicals and ROS. 32 These results point out that, as in well-oxygenated (aerobic) tumor regions, 33 PRXD2 might be a 'metabolic adaptor' with a pathogenic role in lung metastasis acting through its ROS scavenger function of cancer cells, which reach the inhospitable lung microenvironment.
The low metastatic burden of BO2/PRDX2 cells in bones suggests that PRDX2 might interfere in the preferential bone metastatic cells metabolism with deleterious consequences to carcinoma cells that try to adapt to the bone microenvironment. It has recently been reported that mitochondrial glucose oxidation may be incompatible with the survival of some cancer cell. 34 Moreover, the balance mechanism of the antioxidant system might prevent collapse by redirecting the glycolytic flux into the pentose phosphate pathway. 35 Indeed, BO2/GFP cells displayed low glucose dependence suggesting a metabolic shift from glucose oxidation to fatty acid oxidation to resist metabolic insults in a hypoxic and hypoglycemic tissue like bones. Although PRXD2 interfered with BO2 cell bone metastasis progression, we did not observe lung metastasis because the aggressiveness of the cells limited the length of the experiment. Thus, we suggest that PRXD2 protects lung metastatic cells against the lung microenvironment but is not sufficient to induce lung metastasis.
The use of the controversial MBA-MB-435 cell model brings with it the limitations of such a poorly differentiated, aggressive breast tumor line, which expresses both epithelial and melanocytic markers. 36 As 435-P cells grow efficiently via the intra mammary fat path and after tumor removal clinical lung metastasis appears in 470% of the mice, it is a useful standard model that mimics the clinical situation and counteracts the lack of good experimental metastatic breast cancer models. Furthermore, the results are reinforced by those obtained from analyzing the expression of PRXD2 in primary breast tumors, which suggest the association between PRXD2 and lung metastasis.
The mechanism of action of PRDX2 that is associated with its intrinsic role in ROS scavenging might also include the second messenger function of ROS. 37 Molecular mechanisms for ROSmediated control of nuclear factor-kB activity are now beginning to be revealed. 38 Moreover, peroxiredoxins participate in signal transduction to regulate cytochrome release from mitochondria, which is a critical early step in the apoptosis signaling pathway. 39 A proposed model for ROS homeostatic control by PRDXs includes c-Myc-dependent regulation. 40 Furthermore, cytosolic PRDX2 can migrate to the nucleus in stress conditions. In addition to their antioxidant activities, PRDXs participate in various biological functions, such as cell proliferation, differentiation, apoptosis, gene expression and intracellular signaling. 12, 13 PRDX2 positively regulates JNK-dependent DNA repair. 41 Loss of PRDX2 seems to accelerate cellular senescence in vitro in murine fibroblasts by overexpression of negative cell cycle regulators. 42 The higher cell death of shPRDX2 cells, as evidenced by caspase-3 activation in shPRDX2 tumor samples and controls, illustrates an imbalance in tumor turnover favoring the survival of lung metastatic cells overexpressing PRDX2.
In conclusion, we have shown that PRDX2 regulates breast cancer cell colonization in lungs by acting on the oxidative and metabolic stress responses of metastatic cells. Moreover, PRDX2 trend to be expressed in primary tumors, which metastasize in lungs suggesting a putative lung metastasis marker that might be used to stratify patients at first diagnosis. We believe these findings will pave the way to the development of new therapeutic strategies to prevent lung metastasis and improve the response to therapy.
MATERIALS AND METHODS

Cell lines
MDA-MB-435 cells (435-P) supplied by Dr Fabra (IDIBELL) in 1992 and their metastatic variants established from primary cultures of lung (435-L 2 , 435-L 3 and 435-L 2/5 ), lymph node (435-N) and bone (435-B) metastases, maintained under standard conditions have been described elsewhere. 43 Although controversial, it has recently been demonstrated that MDA-MB-435 cells are a useful breast cancer model and that they express both epithelial and melanocytic markers. 36 In some experiments, we used breast cancer bone metastatic cell lines MDA-MB-231 originally obtained from the European Type Culture Collection (ECACC 92020424) in 2007, maintained in accordance with ECACC guidelines for o4 months before use in these experiments. BO2 cell line has been established from bone metastases caused by 231-P after six in vivo passages in nude mice using a heart injection model. The characteristics of luciferase-expressing MDA-BO2 cells have been described elsewhere. 44, 45 Cells were cultured under standard conditions.
Cell viability assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used as described elsewhere. 46 The cells were serum starved for FDG is used to target tumors cells that have a high glycolytic metabolism, whereas NAF is a radiopharmaceutical that has a high affinity to bone. The PET scan of animals did not show any accumulation of FDG in metastatic hind limbs, despite the presence of BLI-positive tumor cells. In contrast, there was far greater accumulation of NAF, which confirms the presence of osteolytic lesions. Intracellular ROS measurement ROS generation in cells was assessed as described elsewhere 47 using two probes: DCFH 2 -DA (Molecular Probes, Alcobendas, Spain) and dihydroethidium (Sigma-Aldrich, St Louis, MO, USA). These probes react specifically with H 2 O 2 to induce the highly fluorescent DCF or ethidium.
Cell transfections and constructs
Retroviral transduction was used to label 435-L 3 lung metastatic cells. Vector preparation and packaging of viral particles was performed as described previously. 48 A cell population that uniformly expressed the highest levels of enhanced GFP (435-L 3 -eGFP-CMV/Luc) was selected by FACS (MoFlo, Cytomation, Dako, Denmark).
Short hairpin RNA and corresponding scrambled sequences directed at PRDX2 target sites based on the human transcript (GI:33188450) were designed using the online small interfering RNA Target Designer software (Promega Corporation, Madison, WI, USA). Sequence analysis confirmed the sequence integrity of the PRDX2 short hairpin RNA plasmids. Plasmids were transfected into 435-L 3 peGFP-CMV/Luc cells using Lipofectamine 2000 reagent.
To overexpress PRDX2 a complementary DNA fragment encoding PRDX2 (transcript variant 1, GI:33188450) was isolated by reverse transcriptase --PCR. The PCR-amplified fragment was digested and cloned into the bidirectional pBI-L vector (Clontech, Hampshire, UK). Stable BO2-GFP/tTA cells were then co-transfected with the pBiL/PRDX2 construct and a plasmid conferring puromycin resistance (Promega Corporation) so that they would express PRDX2 and luciferase. 45 In vivo mouse models, bioluminescence and PET imaging Six-week-old athymic nude Balb/c female mice were used with the approval of the animal care committee.
For the tumorigenesis experiments, cells (10 6 cells in 50 ml serum-free medium) were inoculated intra-mammary fat pad into anesthetized nude mice. 49 Mice were controlled periodically during the experiment until symptoms of metastasis appeared, and metastasis development was monitored by non-invasive bioluminescence imaging. 50, 51 Osteolytic lesions were identified on radiographs as demarcated radiolucent lesions in the bone and the extent of bone destruction per animal was expressed in square millimeters, as described previously. 44, 50 In vivo optical imaging of nude mice engrafted with 435 cells was performed as described previously. 52 The quantification and analysis of the photons recorded in the images was performed using Wasabi image analysis software (Hamamatsu Photonics, Hamamatsu City, Shizuoka Prefecture, Japan). The number of photons was expressed as photon counts and data were expressed as the number of photon counts vs the number of grafted cells. For the image quantification, we calculated the average number of photon counts per pixel of a selected area of interest, using Wasabi image analysis software (average photon counts per pixel).
PET were performed with the ClearPET commercially available system with a spatial resolution at the center of 1.3 mm. Mice were injected with 400 mCi of 2-deoxy-2[ 18 F]fluoro-D-glucose ([ 18 F]FDG) or sodium [ 18 F]fluoride ion (Na 18 F) via the tail vein.
Protein expression in cells and tissues
The specific antibodies used were: anti-PRDX1 to -6, anti-PRDX-SO 3 (LabFrontier, Seoul, Korea), anti-AOP1, anti-a-tubulin, anti-b-actin (Sigma), anti-proliferating cell nuclear antigen (Santa Cruz, Santa Cruz, CA, USA), anti-CD-31/PECAM-1 (BD Pharmingen, San Jose, CA, USA) and anti-caspase-3 (Cell Signaling, Boston, MA, USA).
Statistical analysis
The unpaired Student's t-test and one-way analysis of variance were used to analyze in vitro experiments, and the results were presented as mean ± s.e.m. Analyses were performed using Stat View v5.0 software (www.programas-gratis.net/b/statview-v5). For the in vivo experiments, parametric and non-parametric tests were applied to assess the observed differences in tumor volume at a specific time. For this purpose, we used the Student's t-test and the Wilcoxon test. Furthermore, to evaluate the effect of the differences over time we fitted linear mixed models, 53 which took into account the random effects because of within-mice variation, For metastatic cells to grow in lungs, the cancer cells must possess high levels of redox scavenging molecules that allow adaptation to a microenvironment with functional oxidative phenotype. The overexpression of PRDX2 in lung metastatic cells has pathogenic role acting through its ROS scavenger function. Its unique ability to remove ROS subtends the use of glucose, exerting an effective antioxidant defense system needed to protect metastatic cells from free radicals and ROS. As PRDX2 knockdown dramatically decreases lung metastasis formation, PRXD2 might be a 'metabolic adaptor' , which stabilizes the redox state required for cell survival, then allowing metastasis to progress and shortening the metastasis dormancy period.
PRDX2 promotes lung metastasis V Stresing et al given the repeated measures data structure in the experimental design. Estimated parameters and their variability were used to solve specific contrasts based on likelihood estimation. Thus, we could assess whether the difference was consistent throughout the period, and adjust the effect of time itself in the model. All analyses were performed using the statistical package R. 54 Data and code from these analyses are available on request to the authors. Statistical significance was set at Po0.05.
